Adquey (Difamilast) is a topical phosphodiesterase-4 (PDE4) inhibitor developed for the treatment of atopic dermatitis (AD) in adult and pediatric patients aged 2 years and older. Adquey delivers targeted anti-inflammatory and antipruritic effects with a rapid onset of action, resulting in significant clinical improvement within the first week of treatment.

Difamilast works by selectively inhibiting the PDE4 enzyme, reducing inflammatory cytokine production, and helping to relieve itching, redness, and skin inflammation associated with AD. Phase 2 and Phase 3 clinical trials have demonstrated that difamilast ointment is both effective and well-tolerated, supporting its potential for long-term management of atopic dermatitis.